Results 11 to 20 of about 249,886 (308)

Immunomodulatory therapies for COVID-19

Frontiers in Medicine, 2022
PurposeAs COVID-19 disease progresses, the host inflammatory response contributes to hypoxemia and severe and critical illness. In these latter stages of disease, patients may benefit from immunomodulatory therapies to control the aberrant host inflammatory response. In this review, we provide an overview of these therapies and provide summaries of the
Poonam Mathur, Shyamasundaran Kottilil
openaire   +3 more sources

Multiple sclerosis and COVID-19

Biomedical Papers, 2020
This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we ...
Jan Mares, Hans-Peter Hartung
doaj   +1 more source

Immunomodulatory Therapy for MIS-C

Pediatrics, 2023
CONTEXT Studies comparing initial therapy for multisystem inflammatory syndrome in children (MIS-C) provided conflicting results. OBJECTIVE To compare outcomes in MIS-C patients treated with intravenous immunoglobulin (IVIG), glucocorticoids, or the
Ouldali, Naïm, Son, Mary Beth F., Mcardle, Andrew, Vito, Ortensia, Vaugon, Esther, Belot, Alexandre, Leblanc, Claire, Murray, Nancy, Patel, Manish, Levin, Michael, Randolph, Adrienne, Angoulvant, François   +11 more
openaire   +5 more sources

Clinical and immunological efficacy of immunotherapeutic program after surgical treatment of children with various forms of acute peritonitis

Медицинская иммунология, 2022
Acute peritonitis (AP) is among the most frequent and severe conditions in pediatric abdominal surgery. Due to development of antibiotic resistance and increasing number of atypical infectious and inflammatory diseases (IIDs), a lot of specialists ...
I. V. Nesterova, G. A. Chudilova, V. N. Chapurina, S. V. Kovaleva, Yu. V. Teterin, N. K. Barova, D. E. Lyagusha, V. A. Tarakanov   +7 more
doaj   +1 more source

Efficacy and Safety of Infliximab in HLA-B27-associated Ocular Inflammation Refractory or Intolerant to Conventional Immunomodulatory Therapy

Journal of Ophthalmic & Vision Research, 2020
Purpose: To determine the efficacy and safety of infliximab therapy in patients with HLA B-27-associated ocular inflammation resistant or intolerant to conventional immunomodulatory therapy.
Asima Bajwa, Arash Maleki, Abhishek R Payal, Adriana Fandiño, María Inés Menéndez Padrón, Marisa Walsh, C Stephen Foster   +6 more
doaj   +1 more source

Characterization and profiling of immunomodulatory genes of equine mesenchymal stromal cells from non-invasive sources [PDF]

, 2014
Introduction: Mesenchymal stromal cells (MSCs) have been extensively studied for their promising capabilities in regenerative medicine. Although bone marrow is the best-known source for isolating equine MSCs, non-invasive alternative sources such as ...
De Schauwer, Catharina, Goossens, Karen, Govaere, Jan, Hoogewijs, Maarten, Meyer, Evelyne, Piepers, Sofie, Smits, Katrien, Van de Walle, Gerlinde, Van Soom, Ann   +8 more
core   +2 more sources

Vitamin D supplementation in systemic lupus erythematosus patients with vitamin D deficiency and insufficiency : the effect on disease activity, fatigue and interferon signature gene expression [PDF]

, 2019
Background: Vitamin D deficiency is highly prevalent among patients with systemic lupus erythematosus (SLE) [1]. Evidence from multiple studies has shown that vitamin D deficiency in SLE is associated with a higher disease activity [2].
Borg, Andrew, Camilleri, Liberato, Magro, Rosalie, Saliba, Christian, Scerri, Christian   +4 more
core   +1 more source

The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination

Frontiers in Medicine, 2023
ObjectivesThis study aimed to assess the duration of humoral responses after two doses of SARS-CoV-2 mRNA vaccines in patients with inflammatory joint diseases and IBD and booster vaccination compared with healthy controls.
Selma Tobudic, Elisabeth Simader, Thomas Deimel, Jennifer Straub, Felix Kartnig, Leonhard X. Heinz, Peter Mandl, Helmuth Haslacher, Thomas Perkmann, Lisa Schneider, Thomas Nothnagl, Helga Radner, Florian Winkler, Florian Winkler, Heinz Burgmann, Karin Stiasny, Gottfried Novacek, Walter Reinisch, Daniel Aletaha, Stefan Winkler, Stephan Blüml   +20 more
doaj   +1 more source

Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. [PDF]

, 2016
Low-dose antithymocyte globulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF) preserves β-cell function for at least 12 months in type 1 diabetes.
Atkinson, Mark A, Brusko, Todd M, Gitelman, Stephen E, Gottlieb, Peter A, Haller, Michael J, Hulme, Maigan A, Mathews, Clayton E, Michels, Aaron W, Perry, Daniel J, Posgai, Amanda L, Schatz, Desmond A, Schultz, Andrew R, Shuster, Jonathan J, Wasserfall, Clive H, Zou, Baiming   +14 more
core   +3 more sources

Case report: Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 with severe myocardial dysfunction. Is there any hope in immunotherapy?

Journal of Education, Health and Sport, 2023
Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) develops in a small percentage of children after COVID-19, however, it might cause severe myocardial dysfunction.
Julita Tokarek, Emilian Budny, Renata Szmigielska   +2 more
doaj   +1 more source